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background:  Subcutaneous implantable cardioverter defibrillator (S-ICD) is the latest advancement in defibrillation therapy. It is approved 
for all patients with indications for ICD implantation, without any pacing indications. Despite initial studies showing good safety and efficacy, 
there are limited real world data available. We report our single, high-volume center experience with S-ICD implantation.
Methods:  We retrospectively analyzed data regarding demographics, safety, efficacy and long-term follow-up of patients implanted with 
S-ICD at our center between October 2012 and June 2014.
results:  S-ICD was implanted in 61 patients, with a mean age of 54±16 years (range 19-86). There were 57% males, 56% African-
American and 41% Caucasian. 57% were implanted for primary prevention, 41% had ischemic cardiomyopathy, 39% non-ischemic 
cardiomyopathy, 21% were on dialysis and 20% had prior transvenous device extraction. Mean procedure time was 66±14 minutes. 
Defibrillation threshold testing was performed in 87% of patients. It was initially unsuccessful in 2 patients; repeat testing was successful 
in one with reversed polarity and one required repositioning of the can. Median follow-up was 160 days (range 1-621). Three patients had 
peri-procedural complications- bradycardia requiring temporary pacing, hypercapnic respiratory failure and prolonged hypotension requiring 
ionotropic support. There was no procedural mortality. Two patients died prior to discharge- 1 from intractable ventricular tachycardia due 
to non-revascularizable triple vessel coronary artery disease and 1 from mesenteric ischemia. Three patients died during follow-up (1 from 
asystole and 2 from unknown causes). Four patients had pocket infection with 2 requiring system removal. Eleven patients (18%) received 
shocks- 4 had an appropriate successful shock and 7 had inappropriate shocks (3 from supraventricular tachycardia, 2 from noise sensing 
due to air in the pocket and 2 from T wave oversensing).
Conclusion:  Our data confirms the safety and efficacy of the S-ICD in a real world setting. There are some risks associated with S-ICD 
and careful patient selection is critical to improve long-term success.
